Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: The BRIGHT randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 313, Issue 13, 2015, Pages 1336-1346

  Han, Yaling ^a   Guo, Jincheng ^b   Zheng, Yang ^c   Zang, Hongyun ^d   Su, Xi ^e   Wang, Yu ^f   Chen, Shaoliang ^g   Jiang, Tiemin ^h   Yang, Ping ⁱ   Chen, Jiyan ^j   Jiang, Dongju ^k   Jing, Quanmin ^a   Liang, Zhenyang ^a   Liu, Haiwei ^a   Zhao, Xin ^a   Li, Jing ^a   Li, Yi ^a   Xu, Bo ^l   Stone, Gregg W ^m   Qi, Xiangqian ⁿ   Liu, Chaozhong ^o   Yuan, Jinqing ^a,l,p   more..

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^d The 463 Hospital of Chinese PLA   (China)

^e WUHAN ASIA HEART HOSPITAL   (China)

^f CHINESE PLA GENERAL HOSPITAL   (China)

^g NANJING MEDICAL UNIVERSITY   (China)

^h Affiliated Hospital of Logistics University of CAPF   (China)

ⁱ CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^j GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^k The 210th Hospital of PLA   (China)

^l FUWAI HOSPITAL   (China)

^m NewYork Presbyterian Hospital   (United States)

ⁿ Taida Hospital   (China)

^o AIR FORCE GENERAL HOSPITAL   (China)

^p Excellent Med Sci Service Co   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; TIROFIBAN; ANTITHROMBIN; FIBRINOLYTIC AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TYROSINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BRAIN DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT THROMBOSIS; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED; MYOCARDIAL INFARCTION;

AGED; ANTITHROMBINS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; RECOMBINANT PROTEINS; TYROSINE;

EID: 84927551392     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.2323     Document Type: Article

References (34)

1. Steg PG, James SK, Atar D, et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acutemyocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-2619.
2. O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA guideline for the management of ST-elevationmyocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2013;61(4):485-510.
3. Hamm CW, Bassand JP, Agewall S, et al; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32(23): 2999-3054.
4. Amsterdam EA,Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64 (24):e139-e228.
5. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774-782.
6. Verheugt FW, Steinhubl SR, Hamon M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and access site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4(2):191-197.
7. Ndrepepa G, Schuster T, Hadamitzky M, et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012;125(11): 1424-1431.
8. Yoon YH, Kim YH, Kim SO, et al. Impact of in-hospital bleeding according to the bleeding academic research consortium classification on the long-term adverse outcomes in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2015;85(1):63-71.
9. Stone GW,Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acutemyocardial infarction. N Engl J Med. 2008;358(21):2218-2230.
10. Stone GW,Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acutemyocardial infarction (HORIZONS-AMI). Lancet. 2011;377(9784):2193-2204.
11. Steg PG, van 't Hof A, Hamm CW, et al; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl JMed. 2013;369(23):2207-2217.
12. Zeymer U, Van 't Hof A, Adgey J, et al. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevationmyocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Eur Heart J. 2014;35(36):2460-2467.
13. Clemmensen P, Wiberg S, Van't Hof A, et al. Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention: insights from the EUROMAX Trial (European Ambulance Acute Coronary Syndrome Angiography). JACC Cardiovasc Interv. 2015;8(1 pt B):214-220.
14. Shahzad A, Kemp I, Mars C, et al; HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014; 384(9957):1849-1858.
15. Collet JP, Cuisset T, Rangé G, et al; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100-2109.
16. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23): 2736-2747.
17. Cutlip DE,Windecker S, Mehran R, et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
18. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in -ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation. 2009;119(14):1873-1882.
19. Stone GW, Mehran R, Goldstein P, et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. J AmColl Cardiol. 2015;65(1):27-38.
20. Marso SP, Amin AP, House JA, et al; National Cardiovascular Data Registry. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2010;303(21):2156-2164.
21. Bangalore S, Pencina MJ, Kleiman NS, Cohen DJ. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with -ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. Circ Cardiovasc Interv. 2014;7(3):365-373.
22. Wise GR, Schwartz BP, Dittoe N, et al. Comparative effectiveness analysis of anticoagulant strategies in a large observational database of percutaneous coronary interventions. J Interv Cardiol. 2012;25(3):278-288.
23. Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-center trials show larger treatment effects than multicenter trials. Ann Intern Med. 2011;155(1):39-51.
24. Bellomo R,Warrillow SJ, Reade MC. Why we should be wary of single-center trials. Crit Care Med. 2009;37(12):3114-3119.
25. Bangalore S, Toklu B, Kotwal A, et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: ameta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ. 2014. doi:10.1136/bmj.g6419.
26. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98(3):352-356.
27. SorichMJ, Rowland A, McKin RA, WieseMD. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: ameta-analysis. Circ Cardiovasc Genet. 2014;7(6):895-902.
28. Kimmelstiel C, Zhang P, Kapur NK, et al. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2011;4(2):171-179.
29. Heestermans AA, vanWerkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevationmyocardial infarction. Thromb Res. 2008;122(6):776-781.
30. Bittl JA, Strony J, Brinker JA, et al; Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333(12): 764-769.
31. Stone GW, Clayton T, Deliargyris EN, et al. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: the HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in AcuteMyocardial Infarction). J AmColl Cardiol. 2014;63(1):15-20.
32. Stone GW, McLaurin BT, Cox DA, et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21): 2203-2216.
33. Kastrati A, Neumann FJ, Schulz S, et al; ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for -ST-elevation myocardial infarction. N Engl J Med. 2011;365(21): 1980-1989.
34. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevationmyocardial infarction. Circ Cardiovasc Interv. 2012;5(6):797-804.